Press release - September 12th, 2013
Cerbomed GmbH at the 86th Congress of the German Society of Neurology
ERLANGEN/DRESDEN, Germany, September 12th, 2013 – At the 86th congress of the German Society of Neurology in Dresden the medical device company cerbomed GmbH, Erlangen, Germany, will present a further therapy option for patients suffering from hard-to-treat neurological and psychiatric illnesses: Between September 18th and 21st participants will get first-hand information about the transcutaneous Vagus Nerve Stimulation (t-VNS).
The t-VNS offers a therapy option for patients suffering from epilepsies, depression or pain.
This therapy uses a branch of the vagus nerve that is located closely under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses.
The t-VNS therapy is carried out autonomously by the patients and is easy to integrate into the daily routine. The advantages of t-VNS: No surgery, no hospitalization, minor side effects.
Cerbomed GmbH is an innovative medical device company located in Erlangen, Germany, that focuses on neuromodulation. The company, founded in 2005, focuses on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard-to-treat neurological and psychiatric illnesses.
The transcutaneous Vagus Nerve Stimulation received the European clearance (CE mark) for the treatment of epilepsies, depression and pain. Currently two clinical studies are carried out regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine.
In September 2012 cerbomed entered into a strategic partnership with Cyberonics, Inc., the global market leader in vagus nerve stimulation.
The therapy device NEMOS is available for treating epilepsies in Germany, Austria and Italy.
Please visit us on www.cerbomed.com.